Ruxolitinib for Graft-Versus-Host Disease
Part of Immune system & allergy clinical trials.
This study looks at how well a medicine called ruxolitinib works for patients with graft-versus-host disease (GVHD)—a condition where donor cells attack your body after a bone marrow or stem cell transplant. The trial aims to understand if ruxolitinib can help control this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute or chronic graft-versus-host disease (GVHD)
- You are currently being treated with or eligible to receive ruxolitinib
- Other specific requirements may be detailed in the full protocol
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This study tests a cream called ruxolitinib on the skin rash caused by graft-versus-host disease (GVHD) after a bone marrow or stem cell transplant. The goal is to see if the cream safely reduces the rash without needing stronger medicines by mouth.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.